Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB Source: Eur Respir J, 57 (1) 2001796; 10.1183/13993003.01796-2020 Year: 2021
Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013
Colorimetric assays for rapid drug susceptibility testing of Mycobacterium tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 167s Year: 2003
Change of M. tuberculosis drug susceptibility spectrum during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006
Evaluation of a molecular assay for detection of rifampin and isoniazid resistant mycobacterium tuberculosis in strains and clinical samples Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Detection of isoniazid or rifampin resistant Mycobacterium tuberculosis in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005
The use of the lytic D29 mycobacteriophages for accelerated determination of the drug sensitivity of tuberculosis mycobacteria to first and second-line anti-TB drugs in clinical isolates obtained after initial cultivation Source: Virtual Congress 2020 – Tuberculosis: part 2 Year: 2020
Rapid resistance detection of Mycobacterium tuberculosis to second-line drugs using the manual mycobacterium growth indicator tube (MGIT) system. Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008
The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005
Comparative analysis of detection of Mycobacterium tuberculosis and rifampin resistance determination through microbiological and molecular genetics methods for pulmonary tuberculosis patients with presence or absence of sputum Source: Annual Congress 2012 - Microbiological advances in the diagnosis of tuberculosis Year: 2012
Comparative analysis of M. tuberculosis drug susceptibility tests results in new multidrug-resistant tuberculosis cases and their confirmed contacts. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis with HPLC technique - comparison to the conventional methods Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001
Comparison of rapid in-house methods for drug susceptibility testing of mycobacterium tuberculosis with gold standards Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007
A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis Source: Eur Respir J, 50 (6) 1701354; 10.1183/13993003.01354-2017 Year: 2017
Evaluation of therapeutic response in isoniazid resistant TB Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4) 1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4) 1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017
The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis. Source: International Congress 2017 – MDRTB: detection and management Year: 2017